See more : TQM Alpha Public Company Limited (TQM.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Xinguang Pharmaceutical Co., Ltd. (300519.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Xinguang Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hafnia Limited (HFIAF) Income Statement Analysis – Financial Results
- Molecular Energies PLC (MEN.L) Income Statement Analysis – Financial Results
- PeptiDream Inc. (4587.T) Income Statement Analysis – Financial Results
- Glucose Health, Inc. (GLUC) Income Statement Analysis – Financial Results
- FlexQube AB (publ) (FLEXQ.ST) Income Statement Analysis – Financial Results
Zhejiang Xinguang Pharmaceutical Co., Ltd. (300519.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.xgpharma.com
About Zhejiang Xinguang Pharmaceutical Co., Ltd.
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health foods. The company offers pharmaceutical products in the areas of cardiovascular and cerebrovascular diseases, and traumatic diseases, covering the aspects of respiratory system, digestive system, urinary system, pediatric diseases, and improving immunity. It also can produce 6 dosage forms with 49 approval numbers for drug production and 2 approval numbers for health food. It offers its products in the form of tablets, granules, syrups, powders, hard capsules, and oral solutions, as well as mixtures, including oral liquids. Zhejiang Xinguang Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Shengzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.40M | 351.49M | 320.88M | 283.08M | 291.26M | 276.26M | 310.87M | 315.31M | 311.48M | 292.11M | 267.94M | 249.85M | 229.62M |
| Cost of Revenue | 158.80M | 169.23M | 142.13M | 126.53M | 132.08M | 124.48M | 123.72M | 109.54M | 106.46M | 106.99M | 119.77M | 134.57M | 139.90M |
| Gross Profit | 111.60M | 182.26M | 178.74M | 156.55M | 159.18M | 151.78M | 187.14M | 205.78M | 205.02M | 185.12M | 148.16M | 115.28M | 89.72M |
| Gross Profit Ratio | 41.27% | 51.85% | 55.70% | 55.30% | 54.65% | 54.94% | 60.20% | 65.26% | 65.82% | 63.37% | 55.30% | 46.14% | 39.07% |
| Research & Development | 15.13M | 15.55M | 13.52M | 12.01M | 15.90M | 17.77M | 17.69M | 15.11M | 14.11M | 11.31M | 12.85M | 0.00 | 0.00 |
| General & Administrative | 2.79M | 2.72M | 3.46M | 2.84M | 4.41M | 3.34M | 4.00M | 4.01M | 4.29M | 5.32M | 5.83M | 25.26M | 19.41M |
| Selling & Marketing | 19.53M | 33.74M | 32.06M | 32.48M | 30.47M | 28.70M | 32.25M | 36.19M | 33.49M | 31.75M | 32.47M | 24.96M | 25.02M |
| SG&A | 22.32M | 36.46M | 35.52M | 35.32M | 34.88M | 32.04M | 36.25M | 40.19M | 37.77M | 37.07M | 38.30M | 50.23M | 44.43M |
| Other Expenses | 0.00 | -1.00M | -626.07K | 2.30M | -359.04K | -185.30K | 14.42K | 6.54M | 498.43K | 1.03M | 2.13M | 6.38M | 358.81K |
| Operating Expenses | 37.47M | 69.10M | 68.00M | 63.05M | 65.70M | 64.89M | 70.85M | 75.68M | 70.26M | 66.53M | 65.67M | 53.14M | 46.63M |
| Cost & Expenses | 196.27M | 238.33M | 210.13M | 189.58M | 197.77M | 189.37M | 194.57M | 185.21M | 176.71M | 173.53M | 185.44M | 187.71M | 186.53M |
| Interest Income | 18.91M | 9.78M | 16.61M | 12.70M | 11.37M | 5.84M | 2.21M | 1.44M | 948.91K | 1.36M | 700.25K | -0.44 | 0.00 |
| Interest Expense | 15.77K | 13.93K | 14.55K | 14.00K | 14.93K | 5.82M | 18.95K | 45.19K | 61.65K | 69.67K | 649.63K | 2.47M | 0.00 |
| Depreciation & Amortization | 14.77M | 14.04M | 12.85M | 12.52M | 10.19M | 7.85M | 6.02M | 5.91M | 5.99M | 5.96M | 5.71M | 2.59M | -15.57M |
| EBITDA | 63.71M | 127.84M | 128.21M | 106.31M | 103.69M | 94.75M | 128.57M | 144.51M | 144.05M | 128.98M | 87.61M | 62.62M | 40.55M |
| EBITDA Ratio | 23.56% | 36.37% | 40.32% | 37.55% | 35.74% | 34.16% | 41.32% | 45.92% | 46.55% | 44.41% | 34.12% | 25.06% | 17.66% |
| Operating Income | 74.13M | 126.60M | 132.58M | 112.49M | 108.63M | 101.04M | 122.51M | 132.01M | 137.60M | 122.08M | 82.33M | 60.03M | 56.12M |
| Operating Income Ratio | 27.42% | 36.02% | 41.32% | 39.74% | 37.30% | 36.58% | 39.41% | 41.87% | 44.18% | 41.79% | 30.73% | 24.03% | 24.44% |
| Total Other Income/Expenses | -972.93K | 14.78M | 23.23M | 23.11M | 16.18M | 14.72M | 14.42K | 6.53M | 398.40K | 870.23K | 2.12M | 5.77M | 358.81K |
| Income Before Tax | 73.16M | 125.60M | 131.96M | 114.80M | 108.27M | 100.86M | 122.53M | 138.54M | 138.00M | 122.95M | 84.45M | 65.80M | 56.48M |
| Income Before Tax Ratio | 27.06% | 35.73% | 41.12% | 40.55% | 37.17% | 36.51% | 39.41% | 43.94% | 44.31% | 42.09% | 31.52% | 26.33% | 24.60% |
| Income Tax Expense | 8.80M | 16.78M | 17.68M | 15.82M | 14.37M | 12.86M | 16.37M | 19.58M | 19.22M | 17.30M | 11.98M | 8.95M | 8.35M |
| Net Income | 64.36M | 108.82M | 114.28M | 98.98M | 93.90M | 88.00M | 106.16M | 118.96M | 118.78M | 105.65M | 72.47M | 56.84M | 46.85M |
| Net Income Ratio | 23.80% | 30.96% | 35.62% | 34.96% | 32.24% | 31.85% | 34.15% | 37.73% | 38.14% | 36.17% | 27.05% | 22.75% | 20.41% |
| EPS | 0.40 | 0.68 | 0.71 | 0.62 | 0.59 | 0.55 | 0.66 | 0.89 | 0.99 | 0.88 | 0.61 | 0.48 | 1.56 |
| EPS Diluted | 0.40 | 0.68 | 0.71 | 0.62 | 0.59 | 0.55 | 0.66 | 0.89 | 0.99 | 0.88 | 0.61 | 0.48 | 1.56 |
| Weighted Avg Shares Out | 160.89M | 160.00M | 160.00M | 160.00M | 160.00M | 159.99M | 160.00M | 133.66M | 119.98M | 120.06M | 119.78M | 119.66M | 0.00 |
| Weighted Avg Shares Out (Dil) | 160.89M | 160.00M | 160.00M | 160.00M | 160.00M | 159.99M | 160.85M | 133.66M | 119.98M | 120.06M | 119.78M | 119.66M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports